PLX: Gunggunge utang jangka dawa Protalix BioTherapeutics Inc.

Protalix BioTherapeutics (PLX) develops therapeutic proteins using plant cells, making the process more cost-effective and safer than conventional methods. The company focuses on bringing treatments for Gaucher disease and other rare pathologies to market. The historical price action of long-term debt is currently at 0.01. A unique biosynthesis patent enables the business to successfully withstand competition from producers of standard biosimilars.

When constructing a defensive portfolio, fundamental screening requires strict control over debt load. This metric aggregates all credit obligations with maturities exceeding twelve months, measuring the level of long-term financial leverage. For Protalix BioTherapeutics (PLX), such resources ensure stable R&D funding and the retention of key research staff for plant platforms. The trend of the company's long-term liabilities on this chart allows for an assessment of the balance between expansion and the risk of asset devaluation.